Trial
CARTITUDE-4
Ciltacabtagene autoleucel (cilta-cel) vs standard of care (PVd or DPd) in relapsed/refractory multiple myeloma after 1-3 prior lines.
Also called: CARTITUDE-4, cilta-cel MM trial
Sparsely connected — only 1 link recorded so far.
In short
- 1What it is: a trial in therapies and applications.
- 2How it connects: acts on 0 and is affected by 1 concepts — mostly 1 therapy.
- 3Where it sits: trial on the 15-step immune chain.
What it does
PFS HR 0.26 (74% reduction in progression/death risk); 12-month PFS 76% vs 49%; ORR 84% vs 67%.
Its connections at a glance
Each dot is a concept directly linked to CARTITUDE-4. Colours show the kind of concept.
Learn next
Sources & evidenceloading…
Loading reviewed sources…
Graph ID TR010 · concept status: established. Select any connection above to inspect evidence for that specific link.